About
Titles
Hospital Resident
Education & Training
- MD
- University of Connecticut School of Medicine (2021)
- BS
- Southern Connecticut State University, Biology (2016)
Research
Research at a Glance
Yale Co-Authors
Frequent collaborators of Jonathan Fetene's published research.
Publications Timeline
A big-picture view of Jonathan Fetene's research output by year.
Clemens Bergwitz, MD
Sampada Chande, PhD
Deborah Proctor, MD
Jill Gaidos, MD
Petr Protiva, MD, MPH
Badr Al Bawardy, MD
7Publications
27Citations
Publications
Featured Publications
Impact of COVID-19 Treatment on Real-World Outcomes in Inflammatory Bowel Disease
Sahyoun L, Fetene J, McMillan C, Protiva P, Al Bawardy B, Gaidos J, Proctor D. Impact of COVID-19 Treatment on Real-World Outcomes in Inflammatory Bowel Disease. Digestive Diseases And Sciences 2024, 69: 1654-1660. PMID: 38466459, DOI: 10.1007/s10620-024-08355-3.Peer-Reviewed Original ResearchCitationsAltmetricConceptsSevere COVID-19 infectionInflammatory bowel diseaseCOVID-19 infectionIBD flareIBD therapyCOVID-19 treatmentSingle-center retrospective study of adult patientsMethodsA single-center retrospective studyAdvanced therapiesRetrospective study of adult patientsBowel diseaseStudy of adult patientsInflammatory bowel disease therapyDevelopment of severe COVID-19 infectionSevere COVID-19Acute COVID-19Corticosteroid useNo significant differenceNo therapyAdult patientsSupplemental oxygenPrimary outcomeSecondary outcomesTherapyCorticosteroids
2023
- Price, C., Smith, R., Huang, J., Chan, E., & Fetene, J.Peer-Reviewed Original Research
S1000 Exploring the Influence of COVID-19 Treatment on Real-World Outcomes in IBD Patients: A Comprehensive Analysis
Sahyoun L, McMillan C, Fetene J, Protiva P, Al-Bawardy B, Gaidos J, Proctor D. S1000 Exploring the Influence of COVID-19 Treatment on Real-World Outcomes in IBD Patients: A Comprehensive Analysis. The American Journal Of Gastroenterology 2023, 118: s757-s757. DOI: 10.14309/01.ajg.0000953640.32433.d2.Peer-Reviewed Original Research
2021
Phosphorus bioaccessibility measured in four amino acid–based formulas using in-vitro batch digestion translates well into phosphorus bioavailability in mice
Chande S, Dijk F, Fetene J, Yannicelli S, Carpenter TO, van Helvoort A, Bergwitz C. Phosphorus bioaccessibility measured in four amino acid–based formulas using in-vitro batch digestion translates well into phosphorus bioavailability in mice. Nutrition 2021, 89: 111291. PMID: 34111672, PMCID: PMC8588148, DOI: 10.1016/j.nut.2021.111291.Peer-Reviewed Original ResearchMeSH Keywords and ConceptsConceptsPhosphorus bioavailabilityAmino acid-based formulaProton pump inhibitorsDigestion modelBioavailability analysisPlasma phosphorus levelsLow phosphorus dietDigestion conditionsBioaccessibilityBioavailabilityStomach acidificationDigestive conditionsIntact fibroblast growth factor 23Phosphorus dietFibroblast growth factor 23Stomach pH.Intact parathyroid hormoneAcid-suppressive medicationsDihydroxy vitamin DGrowth factor 23Phosphorus levelsPhosphorus bioaccessibilityAcidificationPhosphorusIntact fibroblast growth factor
2020
Slc20a1/Pit1 and Slc20a2/Pit2 are essential for normal skeletal myofiber function and survival
Chande S, Caballero D, Ho BB, Fetene J, Serna J, Pesta D, Nasiri A, Jurczak M, Chavkin NW, Hernando N, Giachelli CM, Wagner CA, Zeiss C, Shulman GI, Bergwitz C. Slc20a1/Pit1 and Slc20a2/Pit2 are essential for normal skeletal myofiber function and survival. Scientific Reports 2020, 10: 3069. PMID: 32080237, PMCID: PMC7033257, DOI: 10.1038/s41598-020-59430-4.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsHyp miceMuscle functionSkeletal muscleMyofiber functionNormal body weightSkeletal muscle atrophyGene dose-dependent reductionConditional knockout miceReduced oxygen consumption rateStimulation of AMP kinaseKnockout miceHypophosphatemic disordersMuscle atrophyERK1/2 activationGrip strengthConditional deletionHormonal changesLow bloodBody weightC2C12 myoblastsMiceFurther evaluationBlood phosphateDependent reductionAMP kinase
2019
Transgenic mouse model for conditional expression of influenza hemagglutinin-tagged human SLC20A1/PIT1
Chande S, Ho B, Fetene J, Bergwitz C. Transgenic mouse model for conditional expression of influenza hemagglutinin-tagged human SLC20A1/PIT1. PLOS ONE 2019, 14: e0223052. PMID: 31613887, PMCID: PMC6793878, DOI: 10.1371/journal.pone.0223052.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsMeSH KeywordsActinsAnimalsBeta-GlobinsBiological TransportBone DensityCalcitriolChickensCytomegalovirusFemaleFibroblast Growth Factor-23Fibroblast Growth FactorsFounder EffectHemagglutinin Glycoproteins, Influenza VirusHumansMaleMiceMice, TransgenicOsteoblastsParathyroid HormonePhosphatesPrimary Cell CulturePromoter Regions, GeneticRabbitsRecombinant Fusion ProteinsSkullTranscription Factor Pit-1TransgenesConceptsPrimary calvaria osteoblastsLoxP-stop-loxPLoxP-STOP-loxP cassetteMouse modelDihydroxy vitamin D levelsHemagglutinin (HABone mineral densityVitamin D levelsInfluenza hemagglutinin (HAConditional mouse modelActivation of transgene expressionElevated plasma PiTransgenic mouse modelPlasma iPTHUrine PiBeta-globin geneSerum calciumWT littermatesMineral densityDays of ageProtein excretionD levelsSemi-quantitative RT-PCRStandard chowTransgenic mice
2017
Intraperitoneal pyrophosphate treatment reduces renal calcifications in Npt2a null mice
Caballero D, Li Y, Fetene J, Ponsetto J, Chen A, Zhu C, Braddock DT, Bergwitz C. Intraperitoneal pyrophosphate treatment reduces renal calcifications in Npt2a null mice. PLOS ONE 2017, 12: e0180098. PMID: 28704395, PMCID: PMC5509111, DOI: 10.1371/journal.pone.0180098.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsConceptsRenal calcificationCompared to WT miceElevated urinary excretionRenal stone diseaseNucleotide pyrophosphatase phosphodiesterase 1WT miceDietary calciumUrinary excretionIntraperitoneal administrationStone diseaseNull miceMouse mutationMiceCalcificationNephrocalcinosisNpt2aDisordersUnrecognized factorsContribution of genotypePresent studyPhosphodiesterase 1PPINpt2cPatientsNephrolithiasis